Fundraising Fox
AN2 Therapeutics
NASDAQ: ANTXMenlo Park, US · Founded 2019 · Incorporated in Delaware · 38 employees on LinkedIn · Public · 7 known investors
Find your way into AN2 Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Ask Kevin Craig to introduce you to Josh Eizen
You →Kevin · together at GW Pharmaceuticals plc →Josh
Ask Jamie Chen to introduce you to Cameron Trenor
You →Jamie · together at Cellarity →Cameron
Ask Sam Okafor to introduce you to Eric Easom
You →Sam · together at InteKrin Therapeutics, Inc. →Eric
- Lucy O. Day75 people can intro you
Sign up to find every way you can get introduced to AN2 Therapeutics
- Your email: who you already know at AN2 Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the AN2 Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders. It targets diseases with significant unmet medical needs.
Also known as AN2
Founders & leadership
AN2 Therapeutics was founded in 2019 by Joseph S. Zakrzewski, Eric Easom, George H. Talbot, and Michael R.K. (Dickon) Alley.
Board
Investors · 7
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: RA Capital's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Funding
SEC filings, press & company announcements$40M disclosed across 1 of 3 rounds · 2019–2026
▶$40MraisedMar 2026 · 16 investors · PharmaceuticalsRule 506(b)
- Margaret FitzPatrickDirector
- Patricia MartinDirector
- Melvin SpigelmanDirector
- Gilbert Lynn MarksDirector
- Stephanie WongDirector
- Joseph S. ZakrzewskiDirector
- Joshua EizenExecutive Officer
- Kabeer AzizDirector
- Rob ReadnourDirector
- Sanjay ChandaExecutive Officer
- Lucy DayExecutive Officer
- Eric EasomExecutive Officer, Director
- Offering amount
- $40M
- Amount sold
- $40M
- Sales commissions
- $2.4M
- Placement agents
- Leerink Partners LLC
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Company profile
researched Aug 2026AN2 Therapeutics is a biopharmaceutical company based in Menlo Park, California, developing novel therapies from a boron chemistry platform. The company describes a pipeline of boron-based compounds intended to address hematology, infectious disease and oncology indications, with a stated aim of delivering drugs for critical unmet medical needs and improved health outcomes.
Disclosed pipeline programs include epetraborole and AN2-502998, an oral candidate. The company maintains clinical trial, presentation and publication resources alongside an expanded access policy.
Business model
The company develops proprietary small-molecule drug candidates from its boron chemistry platform and lists a business development contact for partnering, alongside internal pipeline programs such as epetraborole and AN2-502998.
▸Full profile — market position, technology, go-to-market, geography
Market position
AN2 Therapeutics positions its boron-based compounds as potential best-in-class therapeutics across hematology, infectious disease and oncology.
Technology
The company's drug discovery is built on a boron chemistry platform, which it describes as suited to delivering novel, potentially first-in-class targets and best-in-class boron-based compounds.
Go-to-market
Patients with hematologic diseases, infectious diseases and cancers characterized by significant unmet medical need.
Geography
Headquarters and offices at 1300 El Camino Real, Suite 100, Menlo Park, California 94025, United States.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Related companies · 3
Companies working in the same space as AN2 Therapeutics.
▸Research sources · 1
primary sources listed
- AN2 Therapeuticsan2therapeutics.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does AN2 Therapeutics do?
- AN2 Therapeutics develops boron-based small-molecule therapies for hematology, infectious disease and oncology.
- Who founded AN2 Therapeutics?
- AN2 Therapeutics was founded by Joseph S. Zakrzewski, Eric Easom, George H. Talbot, Michael R.K. (Dickon) Alley in 2019.
- Who are AN2 Therapeutics's investors?
- AN2 Therapeutics's investors include Adjuvant Capital, BioRock Ventures, Flucas Ventures, Mountain Group Capital, RA Capital, Biotechnology Value Fund, Hatteras Venture Partners.
- How much funding has AN2 Therapeutics raised?
- AN2 Therapeutics has disclosed $40M raised across 1 of its 3 known rounds.
- Is AN2 Therapeutics publicly traded?
- Yes — AN2 Therapeutics trades on NASDAQ under the ticker ANTX.
- Where is AN2 Therapeutics headquartered?
- AN2 Therapeutics is headquartered in Menlo Park, US.